Navigation Links
Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
Date:4/25/2012

CANTON, Conn., April 25, 2012 /PRNewswire/ -- Kelyniam (Pinksheets: KLYG.PK), is pleased to announce first quarter 2012 revenues of $210,635, a four-fold increase from the fourth quarter of 2011.  The increase in revenues was driven by surgeries at new hospitals and from surgeons who have converted to using the Kelyniam Custom Skull Implant made from PEEK material. The first quarter 2012 represents the first full quarter with the new management and a full sales force.

We expect the growth to continue as we gain ground in the domestic custom cranial implant market.  We are currently working on reaching out to the international market this year and believe this will have a direct positive benefit to our bottom line.
"Kelyniam is extremely excited to open up new markets and hopes to capitalize on those with new product lines in the near future, stated President and CEO Tennyson Anthony.

Mark Chenoweth, Vice President of Sales commented,  "We continue to make significant progress in building our presence in hospitals, teaching institutions, and trauma centers across the U.S. The weekly feedback we receive from surgeons who are using our implants has been excellent. They are realizing the benefits of our fast turnaround capabilities, and are thrilled with the time and effort we save them in the O.R. due to our precision fitting implants.
With our unique product offering, we look forward to another exciting 2nd Quarter, providing both the surgeons and patients the best custom skull implant option available in the market today." 

The CPA firm, Sadler, Gibb & Associates, has compiled the balance sheet and income statement for Kelyniam for the period end March 31, 2012.  No audit has been performed on the statements presented.KELYNIAM GLOBAL, INC.Balance SheetsASSETSMarch 31,2012CURRENT ASSETSCash

$

35,303Accounts receivable, net95,728Inventory25,512Other current assets11,111Total Current Assets167,654PROPERTY AND EQUIPMENT, net525,661OTHER ASSETSDistributer rights, net44,005Total Other Assets44,005TOTAL ASSETS

$

737,320LIABILITIES AND STOCKHOLDERS' DEFICITCURRENT LIABILITIESAccounts payable and accrued expenses

$

105,080Accrued interest11,966Other current liabilities35,000Notes payable, current portion77,585Total Current Liabilities229,631LONG-TERM LIABILITIESNotes payable92,018Convertible notes payable, net147,500Total Long-Term Liabilities239,518TOTAL LIABILITIES469,149STOCKHOLDERS' DEFICITCommon stock; $0.001 par value, 60,000,000 shares  authorized; 16,696,235 and 17,152,235 shares issued  and outstanding, respectively17,153Additional paid-in capital2,299,428Deficit accumulated during the development stage(2,048,410)Total Stockholders' Deficit268,171TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT

$

737,320 KELYNIAM GLOBAL, INC.Statements of OperationsFor the Three Months EndedMarch 31,2012REVENUES

$

210,635COSTS OF GOODS SOLD113,006GROSS MARGIN97,629OPERATING EXPENSESDepreciation and amortization33,956Professional fees18,601Commissions, salaries and wages138,268General and administrative expense63,375Total Operating Expenses254,200OPERATING LOSS(156,571)OTHER INCOME (EXPENSE)Interest expense(37,548)Total Other Income (Expense)(37,548)NET LOSS BEFORE INCOME TAXES(194,119)Provision for income taxes-NET LOSS

$

(194,119)BASIC AND DILUTED LOSS PER SHARE

$

(0.01)WEIGHTED AVERAGE NUMBEROF SHARES OUTSTANDING17,100,061A proxy has been distributed to shareholders of record March 27th regarding the annual meeting scheduled for May 11th at the company's headquarters.  Shareholders are reminded to vote and return proxies no later than 2pm EST on May 9, 2012.

About Kelyniam Global, IncorporatedKelyniam Global (Pinksheets: KLYG), Inc. specializes in the use of CAD/CAM technology to provide patient specific custom implants to assist medical professionals by allowing them to operate more effectively, improve patient care, and reduce health care costs by providing the highest quality products available with today's technology. The company is continually researching and developing new products and processes to help patients live more active and productive lives.

Please visit our website at www.kelyniam.com for more information.

Forward-Looking StatementsExcept for historical information contained in this release, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this release, words such as "anticipate," "believes," "estimate," "expect," "should," "intend," "projects," "objective" and "appears" and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions; the impact of competitive products and pricing; capacity and supply constraints or difficulties; product development, commercialization or technological difficulties; the regulatory and trade environment; the impact of reimbursement rates and coverage; and the risk factors reported from time to time in the Company's SEC reports. The Company undertakes no obligation to revise any forward-looking statements as a result of future events or developments.

For Question regarding this Press Release, please contact:

Kelyniam Global Inc.
Michael Hamblett, 800-280-8192  x3
Director of Investor Relations


'/>"/>

SOURCE Kelyniam Global Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Kelyniam Makes History With Revolutionary 24-Hour Turnaround Capabilities
2. Kelyniam Global Inc. Reports 2011 3rd & 4th Quarter Financial Results
3. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
4. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
5. Directors Forum: PEPFAR and the Global AIDS Response
6. Alfacell Corporation to Present at UBS Global Life Sciences Conference
7. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
8. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
9. President Clinton Highlights MWW Group at the 2007 Clinton Global Initiative for its Stop Neglected Tropical Disease Campaign
10. Hillary Clinton Pledges Bold Approach to Stopping HIV/AIDS & Global Poverty
11. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Dehaier Medical Systems ... "Company"), which develops, markets and sells medical devices and ... , signed a strategic cooperation agreement with Hongyuan Supply ... Supply Chain") on June 20, 2016, to develop Dehaier,s ... strategic cooperation agreement, Dehaier will leverage Hongyuan Supply Chain,s ...
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/23/2016)... , June 23, 2016 Research and ... Global Market - Forecast to 2022" report to their ... treatment method for the patients with kidney failure, it replaces ... fluid from the patient,s blood and thus the treatment helps ... and chloride in balance. Increasing number of ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... ... "FCPX editors can now reveal their media with growing colorful split screen ... - CEO of Pixel Film Studios. , ProSlice Color brings the split screens ... reveal the media of their split screens with growing colorful panels. , ProSlice Color ...
(Date:6/26/2016)... (PRWEB) , ... June 27, 2016 , ... Quality metrics ... yet in many ways they remain in the eye of the beholder, according to ... a publication of The American Journal of Managed Care. For the full issue, ...
(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... ... fertility once they have been diagnosed with endometriosis. These women need a treatment ... also require a comprehensive approach that can help for preservation of fertility and ...
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/24/2016)... Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... surgery procedures that most people are unfamiliar with. The article goes on to state ... procedures, but also many of these less common operations such as calf and cheek ...
Breaking Medicine News(10 mins):